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ABSTRACT
Objective: The aim of the study was to examine treatment continuation and satisfaction over 1
year among women receiving nomegestrol acetate (NOMAC)/oestradiol (E2) combined oral contra-
ception (COC) in real-world clinical practice.
Methods: The 17b-Estradiol and Nomegestrol Acetate (BOLERO) Study is an observational, non-
interventional, prospective, multicentre cohort study of premenopausal women (aged 18–50 years)
who received prescription NOMAC/E2 (2.5mg/1.5mg) for contraception during routine clinical
practice. Assessments were carried out at enrolment and at 3, 6 and 12 months. Probability of
treatment continuation through 12 months (primary outcome) was examined using Kaplan–Meier
survival analysis. Secondary outcomes included treatment satisfaction, menstrual cycle-related
symptoms, libido and adverse events (AEs).
Results: Of 298 enrolled women, 292 were evaluable. The probability of NOMAC/E2 continuation
through 12 months was 73.7% (95% confidence interval [CI] 68.0%, 78.5%). Satisfaction with
NOMAC/E2 increased from 56.9% (37/65) of women at initial evaluation to 89.2% (58/65) of
women at 12 months. Physician ratings at 12 months showed satisfactory to very satisfactory in
84.0% (168/200) of women. Libido was not affected. Menstrual cycle-related symptoms significantly
declined from enrolment (6.04±4.32) to 3 months (3.25± 3.05) and 12 months (2.62± 2.74;
p< .0001). Treatment-related AEs were reported by 38.7% (113/292) of women.
Conclusion: The real-world experience of women receiving NOMAC/E2 indicated very good treat-
ment continuation, high satisfaction and significantly improved menstrual cycle-related symptoms.
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Introduction
Combined oral contraception (COC) continues to be a fre-
quently selected contraceptive method among European
women [1]. The evolution in COC formulations to improve
safety and tolerability has included ethinylestradiol (EE) and
progestin dose reductions, development of new progestins
and varied dosing regimens [2]. More recently, COC based
on oestradiol (E2), structurally identical to endogenous
17b-E2, has become available [3]. Nomegestrol acetate
(NOMAC)/E2 (Zoely; Teva Italia, Milan, Italy), approved by
the European Medicines Agency in 2011, is the first mono-
phasic 24/4 day COC regimen to use 17b-E2. It has been
shown that E2, micronised to improve bioavailability, has
weak estrogenic effects and a mild metabolic impact on
estrogen-sensitive hepatic proteins [3]. NOMAC, derived
from 19-norprogesterone with almost exclusive binding to
the progesterone receptor, has been shown to be metabol-
ically neutral with no androgenic, estrogenic or glucocortic-
oid activity and with moderate antiandrogenic activity [3].
The efficacy of NOMAC/E2, as well as good menstrual cycle
control, with shorter and lighter withdrawal bleedings and
absence of withdrawal bleeding for some women, has been
demonstrated in randomised, open-label, multicentre trials
that compared NOMAC/E2 with a drospirenone/EE 21/7day
regimen [4,5]. NOMAC/E2 has also been associated with
reduced premenstrual and menstrual symptoms and men-
strual cramping [6,7], as well as improved quality of life [7,8].
NOMAC/E2 contraceptive efficacy was maintained with less
stringent back-up requirements following missed pills, likely
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related to the long half-life of NOMAC (46h) and the 24/4day
regimen of NOMAC/E2 [4,5]. Consistent with this finding,
contraceptive protection is not reduced if the missed NOMAC/
E2 active pill is taken <24h late [9]. Further, compared with
levonorgestrel/EE, NOMAC/E2 has demonstrated significantly
less haemostatic impact (assessed via evaluation of coagula-
tion and fibrinolysis markers), no alteration of carbohydrate
metabolism (assessed using glucose tolerance and insulin
resistance) and a neutral effect on lipid metabolism (assessed
through levels of triglycerides and low- and high-density lipo-
protein cholesterol) [10]. The potential for reduced haemostatic
impact is noteworthy given the continued efforts to reduce
the risk of venous thromboembolism that is moderately asso-
ciated with COC treatment [10].
NOMAC/E2 may help address an ongoing need for COC
formulations that support treatment continuation, given
that concerns about the use of synthetic hormones and
associated side effects are frequently reported by women
as reasons for COC discontinuation [11,12]. Women have
expressed a preference for COC based on natural estrogen,
following contraceptive counselling, primarily because of
fear of synthetic hormones or a desire for decreased bleed-
ing associated with E2-based COC [13]. To address whether
NOMAC/E2 meets these characteristics, the current study
examined treatment continuation and satisfaction over 1
year among women receiving NOMAC/E2 for contraception
in real-world clinical practice.
Methods
Study design and population
The 17b-Estradiol and Nomegestrol Acetate (BOLERO) Study
is an observational, non-interventional, prospective, multi-
centre cohort study conducted in 17 centres in Italy. Eligible
participants were premenopausal women aged 18–50 years,
with or without prior COC use, who were prescribed NOMAC
2.5mg/E2 1.5mg for contraception during routine clinical
practice. Contraceptive treatment selection and consent to
study participation were independent decisions. Women
received their prescription for NOMAC/E2 1 month and <3
months prior to study enrolment. Exclusion criteria included
any condition that contraindicated use of COC and age 35
years in current smokers. Women were recruited over a 15
month period and were followed for a period of 12 months
(13 treatment cycles). Study assessments were carried out at
enrolment and at 3, 6 and 12 months. The end-of-study final
evaluation was completed before 12 months if a woman dis-
continued study participation early.
The study was conducted in full conformance with the
principles of the Declaration of Helsinki, and fully adhered
to the Guideline for Good Clinical Practice, International
Conference on Harmonization Tripartite Guideline and local
laws. Independent ethics committees of the participating
centres approved the study protocol; women provided
informed consent prior to participation in the study.
Assessments
The primary efficacy outcome was continuation of treat-
ment, defined as the number of treatment cycles com-
pleted over 12 months and assessed using a daily diary.
Secondary outcomes included treatment satisfaction, men-
strual cycle-related symptoms and libido. Treatment satis-
faction was assessed with a 7 point scale ranging from
‘very unsatisfactory’ to ‘very satisfactory’ at 3, 6 and 12
months or at the final study visit. Additionally, treating
physicians rated treatment satisfaction at 12 months or at
the final study visit using the Clinical Global Impression
(CGI) 7 point scale that ranged from ‘very unsatisfactory’ to
‘very satisfactory’. Evaluation of menstrual cycle-related
symptoms included headache, breast pain/tenderness,
swelling (abdominal swelling and oedema), dysmenorrhoea
and mood disturbance. Symptoms were assessed using 5
point scales ranging from ‘absent’ to ‘serious’, and the total
symptom score was summed across the individual symp-
toms. The assessment of menstrual cycle-related symptoms
at enrolment was retrospective: women were asked to
assess symptoms related to their last three menstrual
cycles prior to initiating NOMAC/E2. Additionally, treating
physicians rated the degree of improvement in overall
menstrual cycle-related characteristics and symptoms at 12
months or at the final study visit using the CGI 7 point
scale that ranged from ‘much worse’ to ‘much improved’.
Level of libido was rated on a 5 point scale that ranged
from ‘very poor’ to ‘very satisfactory’ at 3, 6 and 12 months
or at the final study visit.
Safety was examined through reports of adverse events
(AEs) from study enrolment to the final study visit.
Treatment emergent AEs (TEAEs) and treatment-related AEs
were assessed. Physicians rated AEs as unrelated (no rea-
sonable possibility) or related (reasonable possibility) to
treatment, and AE severity (mild/moderate/severe) and AE
seriousness (yes/no). AEs were coded by MedDRA version
16.0 (www.meddra.org) and used preferred terms.
Table 1. Demographic and clinical characteristics of women receiving
NOMAC/E2 (N¼ 298).
Characteristic Value
Age, years 29.2 ± 7.4
Age categories, years
25 102 (34.2)
26–30 87 (29.2)
31–35 53 (17.8)
36–40 24 (8.1)
>40 32 (10.7)
Race
Asian 2 (0.7)
Black 2 (0.7)
Caucasian 287 (96.3)
Hispanic 3 (1.0)
Other 4 (1.3)
Smoking, yes 53 (17.8)
Marital status
Single 206 (69.1)
Married 82 (27.5)
Divorced 10 (3.4)
Education
High school 140 (47.0)
Secondary school 38 (12.8)
University 120 (40.3)
Work status
Student 92 (30.9)
Employed 72 (24.2)
Housewife 20 (6.7)
Unemployed 24 (8.1)
Other 90 (30.2)
BMI, kg/m2 21.5 ± 3.1
Systolic blood pressure, mmHg 111.6 ± 10.3
Diastolic blood pressure, mmHg 69.1 ± 7.7
Values are expressed as mean ± SD or n (%).
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Data analysis
The primary outcome of continuation of NOMAC/E2 treat-
ment was assessed using Kaplan–Meier survival analysis
and is reported as the discontinuation-free probability esti-
mate at day 365 with 95% confidence intervals (CIs).
Change in the menstrual cycle-related total symptom score
was examined using general linear models for repeated
measures with 95% CIs. This analysis used a univariate test
for within-subject effects using mixed models (Proc Mixed;
SAS Institute, Cary, NC, USA) to fit models with a variety of
error covariance matrices and evaluate the patterns of
covariance matrices (defined as type H covariances) to sat-
isfy the Huynh–Feldt condition, by applying a sphericity
test. Adjustment to numerator and denominator degrees of
freedom was used to obtain an unbiased estimate of the
effects. Treatment satisfaction, CGI physician ratings and
libido were examined descriptively using percentages
within response categories. AEs were summarised by the
percentage of women experiencing any AE and by individ-
ual AEs. Analyses included all enrolled women and were
completed using SAS version 9.2 or later (SAS Institute,
Cary, NC, USA). Numerical data are expressed as mean-
± standard deviation (SD). For all statistical analyses, p-
values <.05 were considered significant.
Results
A total of 298 women from 17 centres were enrolled
(Tables 1 and 2). The mean age was 29.2 ± 7.4 years, 82.2%
(245/298) of women were non-smokers, 11.1% (33/298)
were overweight (body mass index [BMI] 25.0–30.0 kg/m2)
and 1.7% (5/298) were moderately obese (BMI
30.0–35.0 kg/m2). Previous contraception was reported by
80.5% (240/298) of women, including COC (56.7% [169/
298]), barrier contraception (35.9% [107/298]) and natural
contraceptive methods (10.7% [32/298]). Mean time from
NOMAC/E2 prescription to study enrolment was 44.6 ± 35.0
days. Among the 298 enrolled women, no additional infor-
mation was available for six women. Accordingly, all subse-
quent analyses were performed on 292 women.
Examination of participant disposition showed that 200/292
women (68.5%) continued study participation through 12
months (Figure 1), and study completion was similar
between women with prior COC use (69.5% [116/167] of
women) and women with no prior COC use (67.2% [84/
125]). Reasons for early discontinuation of study participa-
tion included those unrelated to treatment (17/292 [5.8%]),
those related to treatment (51/292 [17.5%]) and those lost
to follow-up (24/292 [8.2%]). Conservatively, women lost to
follow-up were grouped with those with early discontinu-
ation due to treatment.
Treatment continuation
Kaplan–Meier analysis showed that the probability of
NOMAC/E2 continuation from enrolment to day 365 was
73.7% (95% CI 68.0%, 78.5%; Figure 2). Among women
with prior COC use before starting NOMAC/E2, the prob-
ability of treatment continuation to day 365 was 74.2%
(95% CI 67.8%, 80.6%). Among women with no prior COC
use, the probability of treatment continuation to day 365
was 70.7% (95% CI 61.5%, 78.1%).
Treatment satisfaction, menstrual cycle-related
symptoms and libido
Satisfaction with NOMAC/E2 increased from 56.9% (37/65)
of women at the time of initial evaluation performed
Table 2. Menstrual cycle and contraceptive method history of women receiving NOMAC/E2 (N¼ 298).
Medical history Value
Age at menarche, years 12.4 ± 1.4
Cycle type, regular 223 (74.8)
Mean menstruation duration, days 4.9 ± 1.6
Prior pregnancy, yes 80 (26.8)
Prior abortion, yes 44 (14.8)
Use of previous contraception, yes 240 (80.5)
Method of previous contraceptiona
COC 169 (56.7)
Barrier contraception 107 (35.9)
Natural contraceptive method 32 (10.7)
Reason for discontinuation of previous COC (n¼ 169)a
No longer needed contraception (planning pregnancy or no partner) 34 (20.1)
Weight increase 27 (16.0)
Spotting 26 (15.4)
Headache 22 (13.0)
Reduced libido 10 (5.9)
Liquid retention/oedema 10 (5.9)
Poor compliance 9 (5.3)
Desired a different COC 7 (4.1)
Medical symptoms/physician recommendation 7 (4.1)
Acne 6 (3.6)
Vaginal dryness 5 (3.0)
Mood changes 3 (1.8)
Breast tension 2 (1.2)
Nausea 3 (1.8)
Poor efficacy 3 (1.8)
Desired different contraceptive method 2 (1.2)
Otherb 15 (8.9)
Values are expressed as mean ± SD or n (%).
aMultiple responses allowed.
bOther reasons included: participant decision without further explanation (n¼ 6), unknown (n¼ 6),
amenorrhoea (n¼ 1), metrorrhagia (n¼ 1) and dysmenorrhoea (n¼ 1).
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within 3 months of NOMAC/E2 use to 89.2% (58/65) of
women at the final visit performed 12 months after initial
evaluation (Figure 3). Among the 28 women dissatisfied at
enrolment, 92.9% (26/28) were satisfied with treatment at
the final visit; only 13.5% (5/37) of those satisfied at enrol-
ment were dissatisfied at the final visit. Additionally, phys-
ician ratings of each woman’s treatment satisfaction at 12
months showed unsatisfactory in 7.0% (14/200), indifferent
in 9.0% (18/200) and satisfactory to very satisfactory in
84.0% (168/200).
Women reported a significant improvement in men-
strual cycle-related symptoms (p< .0001) during NOMAC/E2
treatment (Table 3). The menstrual cycle-related total symp-
tom rating declined from 6.04 ± 4.32 at enrolment to
3.25 ± 3.05 at 3 months of NOMAC/E2 treatment, and fur-
ther declined to 2.62 ± 2.74 at 12 months. Women with
prior COC use before initiating NOMAC/E2 and women
without prior COC use were similar in their report of men-
strual cycle-related symptoms at enrolment and decline in
symptoms over 12 months with NOMAC/E2 (Table 3).
Physicians rated cycle characteristics and symptoms at 12
months as worsened in 20% (40/200), unchanged in 14.5%
(29/200) and slightly to much improved in 65.5% (131/200)
of women.
292 Women initiated NOMAC/E2
Prior COC use n=167
No prior COC use n=125
200 Women completed 12 months
Prior COC use n=116
No prior COC use n=84
92 Women discontinued
Discontinuation treatment related
Treatment related n=51
Lost to follow-up n=24
Discontinuation not treatment related
Not treatment related n=17
Figure 1. Participant disposition. Reasons for discontinuation of NOMAC/E2 included treatment-related AEs, poor compliance, dissatisfaction and decision to
change contraceptive method. Discontinuation of NOMAC/E2 that was not treatment-related included no longer needed contraception, scheduled surgery and
desire for pregnancy.
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Figure 3. Treatment satisfaction among women receiving NOMAC/E2.
Table 3. Change from enrolment in menstrual cycle-related symptoms of
women receiving NOMAC/E2.
Variable
Total symptom scorea
Mean ± SD
Change from enrolment
95% CI
Women completing the study (n¼ 200)
Enrolment 6.04 ± 4.32 –
Month 3 3.25 ± 3.05 2.25, 3.40
Month 6 2.96 ± 3.13 2.47, 3.59
Month 12 2.62 ± 2.74 2.86, 3.98
Prior COC use (n¼ 116)
Enrolment 5.73 ± 4.05 –
Month 3 3.13 ± 3.08 1.91, 3.44
Month 6 2.94 ± 3.04 1.97, 3.43
Month 12 2.45 ± 2.80 2.53, 4.03
No prior COC use (n¼ 84)
Enrolment 6.47 ± 4.67 –
Month 3 3.41 ± 3.04 2.12, 3.93
Month 6 3.00 ± 3.25 2.59, 4.35
Month 12 2.86 ± 2.65 2.77, 4.46
aMixed model for repeated measures of change from enrolment in total
symptom score, p< .0001. Total symptom score is the sum of the ratings
of the individual symptoms on a 5 point scale ranging from absent to ser-
ious for menstrual cycle-related headache, breast pain/tenderness, swel-
ling, dysmenorrhoea and mood disturbance.
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Libido was not affected by NOMAC/E2 treatment.
Unsatisfactory libido was reported by 14.7% of women at
the enrolment visit and by 10.7% after a follow-up of 12
months (Figure 4).
Safety
TEAEs were reported by 44.2% (129/292) of women; 38.7%
(113/292) of women experienced AEs that were considered
possibly treatment-related. The most common treatment-
related AEs (reported by 2–13% of women) were metror-
rhagia, amenorrhoea, headache, abdominal distension,
breast discomfort, mood changes and acne (Table 4). Less
than 2% of women reported weight gain (n¼ 4; 1.4%) or
decreased libido (n¼ 2; 0.7%). Two serious AEs were
reported, including primary mediastinal large B cell lymph-
oma, considered unrelated to treatment, and a pregnancy.
The pregnancy occurred in a 22-year-old single woman
with a BMI 24.2 kg/m2. She reported that her previous use
of COC had been interrupted for headache. No information
was available on her use of NOMAC/E2 or the preg-
nancy outcome.
Treatment discontinuation due to AEs occurred in 31/
292 (10.6%) women. The AEs most commonly associated
with treatment discontinuation were headache (drug with-
drawal headache, n¼ 1; other headache or migraine,
n¼ 11) and mood changes (n¼ 7). Treatment discontinu-
ation due to metrorrhagia occurred in 3/292 (1.0%) of
women, suggesting that most women with metrorrhagia
were experiencing breakthrough spotting or light bleeding.
Discussion
Findings and interpretation
Efficacious and tolerable COC that supports treatment con-
tinuation, satisfaction and adherence is essential to prevent
COC discontinuation and potential subsequent use of less
effective contraceptive methods [11], and further reduce
the number of unplanned pregnancies. NOMAC/E2 may be
an especially good match for women who prefer COC
based on natural estrogen. In the current study, women
who selected NOMAC/E2 for contraception during routine
clinical practice showed high probability of treatment con-
tinuation from study enrolment to 12 months.
Differences and similarities in relation to other studies
Most women reported satisfaction with NOMAC/E2
throughout the study. This was consistent with the signifi-
cant improvement in menstrual cycle-related symptoms
reported by women and their physicians. The significant
improvement in menstrual cycle-related symptoms, includ-
ing headache, breast pain/tenderness, swelling, dysmenor-
rhoea and mood disturbance, observed at 3 months and
with continued improvement to 12 months, is consistent
with previous studies examining NOMAC/E2 [6,7]. The high
NOMAC/E2 continuation rate is also consistent with the
low frequency of AEs resulting in treatment discontinu-
ation. The report of satisfactory libido by most women in
the current study is in line with the report of improved sex-
ual function among women who chose to switch to
NOMAC/E2 from another COC due to dissatisfaction with
sexual desire during their previous treatment [14]. The
amenorrhoea experienced by some women is similar to
findings from previous NOMAC/E2 studies and is likely
related to the long half-life of NOMAC and 24/4 day
NOMAC/E2 regimen [4,5].
Concern about side effects is frequently reported by
women as their primary reason for COC dissatisfaction and
discontinuation, including concern about side effects
related to EE and consideration of switching contraception
to reduce exposure to hormones [11,12,15–17]. In a real-
world clinical practice study of women in Spain, 21.1% of
women discontinued COC use for treatment-related rea-
sons, including poor cycle control, side effects, method fail-
ure and ‘other’ [18]. In our study of women receiving
NOMAC/E2 in routine clinical practice, treatment-related
reasons for discontinuation, including AEs or other reasons,
was lower at 17.5% of women. Non-treatment-related dis-
continuation in our study, in 5.8% of women, was similar
to a real-world clinical practice study of COC continuation
in Spain that reported 6.6% (including women with preg-
nancy desire and change in sexual habits), whereas our
participants lost to follow-up were fewer (8.2% vs 19.3%)
[18]. The continuation rate of NOMAC/E2 in our study
appears to be comparable to, or higher than, COC continu-
ation rates reported in other population-based cohorts or
real-world studies [16–19].
Strengths and weaknesses of the study
Strengths of this study include the real-world examination
of a large sample of women receiving NOMAC/E2 for
14.7
85.3
12.3
87.7
13.4
86.6
10.7
89.3
0
10
20
30
40
50
60
70
80
90
100
Dissatisfied Indifferent/satisfied
W
om
en
 (%
)
First visit 3 Months 6 Months 12 Months
Figure 4. Libido among women receiving NOMAC/E2.
Table 4. Treatment-related AEs reported by 2% of women receiving
NOMAC/E2 (N¼ 292).
Treatment-related AEa n (%)
Metrorrhagiab 39 (13.4)
Amenorrhoea 28 (9.6)
Headache 25 (8.6)
Drug withdrawal headache 1 (0.3)
Other headache/migraine 24 (8.2)
Abdominal distension 10 (3.4)
Breast discomfort or pain 8 (2.7)
Mood changes 7 (2.4)
Acne 6 (2.1)
aIndividual participants can be included in more than one treatment-related
AE category.
bThe MedDRA preferred term metrorrhagia includes breakthrough bleeding
and spotting.
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contraception during routine clinical practice. Real-world
evaluations of contraceptive outcomes complement the
findings of controlled clinical trials because clinical trial par-
ticipants are often specially selected and may not be repre-
sentative of the general population of COC users, and
clinical trial methods such as free contraception and regu-
lar participant follow-up may not accurately reflect COC
continuation in real life [19,20]. In our study, women
received their prescription for NOMAC/E2 during routine
clinical care and study participants independently answered
questions about their experience with NOMAC/E2. Because
participants were not encouraged to continue NOMAC/E2
or provided with any financial or other support, the effect
of study participation on treatment continuation was prob-
ably minimal.
Real-world prospective observational studies of clinical
practice outcomes also complement findings from retro-
spective health claims database studies. Database studies
provide important information on the use of contraceptive
treatment across large populations of women [21]; how-
ever, many relevant variables, such as change in menstrual
cycle-related symptoms, are not captured in these data-
bases. Such clinical information, necessary to understand-
ing the reasons underlying continuation of COC, as well as
potential targets for contraceptive counselling, can be
gathered in real-world observational studies.
The current observational study excluded women receiv-
ing other COC formulations, which prevented direct com-
parisons among types of COC. The study findings should
be considered preliminary and warrant further comparative
investigation of COC continuation and satisfaction among
women who select NOMAC/E2 vs EE-based COC.
Conclusion
NOMAC/E2 is the first monophasic 24/4 day COC regimen
based on E2, which is structurally identical to the endogen-
ous 17b-E2 that is naturally produced by the ovaries.
Previous studies have indicated a preference for COC based
on natural estrogen among some women, and improved
quality of life among women who switched to COC based
on natural estrogen. In our study, the real-world experience
of women who were prescribed NOMAC/E2 during routine
clinical practice indicated very good treatment continuation
and high satisfaction with treatment through 12 months.
The non-contraceptive benefits of NOMAC/E2 included sig-
nificantly improved menstrual cycle-related symptoms of
headache, breast pain/tenderness, swelling, dysmenorrhoea
and mood disturbance. Our findings provide further evi-
dence that NOMAC/E2 COC meets contraceptive and non-
contraceptive needs and supports treatment continuation
among women seeking contraception based on nat-
ural estrogen.
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